CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 130 filers reported holding CYMABAY THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 2.94 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2022 | $1,072,540 | -82.0% | 171,059 | -90.0% | 0.30% | -81.2% |
Q3 2022 | $5,961,000 | +13.0% | 1,703,235 | -4.7% | 1.60% | +11.6% |
Q2 2022 | $5,273,000 | +0.2% | 1,787,569 | +5.6% | 1.44% | +4.7% |
Q1 2022 | $5,264,000 | -12.9% | 1,692,569 | -5.3% | 1.37% | -9.7% |
Q4 2021 | $6,042,000 | +215.7% | 1,787,569 | +241.0% | 1.52% | +199.0% |
Q3 2021 | $1,914,000 | -14.0% | 524,286 | +2.7% | 0.51% | +9.2% |
Q2 2021 | $2,225,000 | +45.1% | 510,386 | +51.1% | 0.46% | +27.7% |
Q1 2021 | $1,533,000 | +165.2% | 337,770 | +104.0% | 0.36% | +118.0% |
Q2 2020 | $578,000 | -67.7% | 165,600 | -52.7% | 0.17% | -75.2% |
Q3 2019 | $1,792,000 | -28.5% | 349,996 | 0.0% | 0.67% | -28.5% |
Q2 2019 | $2,506,000 | -32.3% | 349,996 | +25.5% | 0.94% | -41.0% |
Q1 2019 | $3,703,000 | +41.5% | 278,811 | -16.1% | 1.60% | +22.8% |
Q4 2018 | $2,617,000 | -19.8% | 332,511 | +12.9% | 1.30% | -2.9% |
Q3 2018 | $3,263,000 | -17.4% | 294,511 | 0.0% | 1.34% | -27.6% |
Q2 2018 | $3,952,000 | -6.1% | 294,511 | -9.1% | 1.85% | -9.6% |
Q1 2018 | $4,207,000 | +26.6% | 323,843 | -10.3% | 2.05% | +14.4% |
Q4 2017 | $3,323,000 | -5.2% | 361,164 | -17.0% | 1.79% | -17.8% |
Q3 2017 | $3,506,000 | +3087.3% | 435,000 | +2181.4% | 2.18% | +2691.0% |
Q2 2017 | $110,000 | -71.0% | 19,067 | -78.3% | 0.08% | -75.7% |
Q1 2017 | $379,000 | – | 88,067 | – | 0.32% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Saturn V Capital Management LP | 1,629,464 | $14,208,926 | 10.61% |
Lynx1 Capital Management LP | 1,369,927 | $11,945,763 | 9.96% |
Versant Venture Management, LLC | 543,753 | $4,741,526 | 9.88% |
Foresite Capital Management IV, LLC | 1,787,094 | $15,583,460 | 8.09% |
Octagon Capital Advisors LP | 4,570,918 | $39,858,405 | 5.74% |
ACUTA CAPITAL PARTNERS, LLC | 878,500 | $7,660,520 | 5.64% |
TCG Crossover Management, LLC | 3,048,257 | $26,580,801 | 5.18% |
Affinity Asset Advisors, LLC | 1,083,118 | $9,444,789 | 3.12% |
Altium Capital Management LP | 620,000 | $5,406,400 | 3.00% |
Bain Capital Life Sciences Investors, LLC | 2,500,000 | $21,800 | 2.72% |